Akari Therapeutics (AKTX) CEO Abizer Gaslightwala Receives Award

What Happened

• Abizer Gaslightwala, CEO and director of Akari Therapeutics (AKTX), was granted an award (transaction code A) of 6,430 American Depositary Shares (ADSs) on 2026-09-29 at a reported value/price of $9.72 per ADS, a total of $62,500. This was a compensation grant (RSU-style award), not an open‑market purchase or sale.

Key Details

• Transaction date and type: 2026-09-29 — Grant/Award (code A)
• Shares/amount: 6,430 ADSs at $9.72 each; total reported value $62,500
• Shares owned after transaction: Not specified in the provided excerpt
• Vesting & restrictions (footnote): These ADSs represent restricted stock units (RSUs). Each RSU is the right to receive underlying ordinary shares; the RSUs vest in four approximately equal quarterly installments on Nov 18, 2026; Feb 18, 2027; May 18, 2027; and Aug 18, 2027, subject to continued service. The RSUs are subject to forfeiture if shareholders do not approve an increase to the equity incentive plan’s reserved shares.
• Timeliness: Filing dated 2026-10-01 for a 2026-09-29 grant — appears timely under Form 4’s two-business-day rule.

Context

• RSU awards are a form of compensation; they do not reflect an immediate market purchase or sale. The holder only receives tradable shares if/when RSUs vest and any plan conditions are met. There is no indication in this filing of a contemporaneous sale, exercise, or tax-withholding sale.